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Research
Randomised controlled trial of four commercial weight loss
programmes in the UK: initial findings from the BBC “diet trials”
Helen Truby, Sue Baic, Anne deLooy, Kenneth R Fox, M Barbara E Livingstone, Catherine M Logan, Ian A
Macdonald, Linda M Morgan, Moira A Taylor, D J Millward
Abstract
Objective To compare the effectiveness of four commercial
weight loss diets available to adults in the United Kingdom.
Design Six month multicentre randomised unblinded
controlled trial.
Setting Community based sample of otherwise healthy
overweight and obese adults.
Interventions Dr Atkins’ new diet revolution, Slim-Fast plan,
Weight Watchers pure points programme, and Rosemary
Conley’s eat yourself slim diet and fitness plan.
Main outcome measures Weight and body fat changes over six
months.
Results All diets resulted in significant loss of body fat and
weight over six months. Groups did not differ significantly but
loss of body fat and weight was greater in all groups compared
with the control group. In an intention to treat analysis, average
weight loss was 5.9 kg and average fat loss was 4.4 kg over six
months. The Atkins diet resulted in significantly higher weight
loss during the first four weeks, but by the end was no more or
less effective than the other diets.
Conclusions Clinically useful weight loss and fat loss can be
achieved in adults who are motivated to follow commercial
diets for a substantial period. Given the limited resources for
weight management in the NHS, healthcare practitioners
should discuss with their patients programmes known to be
effective.
Trial registration Clinical trials NCT00327821.
Introduction
The prevalence of obesity and its comorbidities is increasing in
the United Kingdom.1 Over half of British adults are now
overweight, and half of these people will probably become
obese.2 The estimated cost of obesity is £0.5bn (€0.7bn; $0.9bn)
each year to the NHS and £2bn each year to the wider economy.3
Most adults in the United States diet at some time, and trends
in the UK are similar.4–6 Long term success rates tend to be poor,
with 50% of weight loss being regained within one year.7
With a market estimated to be worth £11.2bn by 2007, it is
not surprising that the commercial sector has shown a keen
interest in weight loss programmes.Weight Watchers, the market
leader, claims to have one million members (P Hunt, personal
communication, 2005). Self help books that provide weight loss
strategies are often best sellers—Dr Atkins’New Diet Revolution has
sold more than 10 million copies.8 Although commercial diets
provide consumers with a plethora of choice, data on their com-
parative efficacy are limited.9
Our study compared four popular commercial weight loss
programmes with a control group. The diets—representative of
the main approaches to weight management in the UK today—
were the Slim-Fast plan (a meal replacement approach), Weight
Watchers pure points programme (an energy controlled diet
with weekly group meetings), Dr Atkins’ new diet revolution (a
self monitored low carbohydrate eating plan), and Rosemary
Conley’s eat yourself slim diet and fitness plan (a low fat diet and
a weekly group exercise class). We report the changes in weight
and body fat over the six month study and describe dieting
behaviour and weight change in the participants at 12 months.
Methods
The trial was an unblinded randomised controlled parallel
dietary intervention study with a delayed treatment control
group conducted at five regional centres (Surrey University, Bris-
tol University, Nottingham University, Ulster (Coleraine) Univer-
sity, and Queen Margaret University College, Edinburgh).
Recruitment strategy
We identified potential participants via a BBC advertising
campaign (television and other forms of media). Participants
were chosen from people who lived within 30 miles of a test cen-
tre, were aged between 18 and 65, and had a self reported body
mass index between 27 and 40. Volunteers who fulfilled these
preliminary inclusion criteria contacted their general practi-
tioner for confirmation that they were eligible. Exclusion criteria
were coronary heart disease; type 1 or type 2 diabetes; renal,
liver, or respiratory failure; gout; obesity with known cause
(Cushing’s disease, hypothyroidism); previous gastric or weight
loss surgery; clinical depression; eating disorders; drug or
alcohol misuse; any malabsorptive state (including lactose intol-
erance); taking lipid lowering or anti-hypertensive drugs; taking
any drugs (including orlistat and sibutramine) for weight loss;
being treated for cancer; and being pregnant or breastfeeding.
Participants gave full informed consent. Three hundred people
returned the necessary documentation to enter baseline testing
by the start date of the study (July 2002).
Protocol assignment
We estimated that 60 initial participants (44 completers) were
needed per treatment group (allowing for a 25% dropout rate)
for an 80% chance of identifying a true difference of 4 kg of body
weight loss (3 kg body fat), with a significance level of 5%. Thus,
each of the five test centres aimed to recruit 60 participants (12
for each diet group; total sample size of 300). Participants took all
baseline tests before randomisation and each centre started the
Cite this article as: BMJ, doi:10.1136/bmj.38833.411204.80 (published 23 May 2006)
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study within six weeks of the start date. Seven participants were
subsequently excluded (fig 1). At each test centre, we stratified
participants by sex and allocated them to a group using random
number generation. Body mass index and age did not differ
between groups or between centres.
It was not possible to blind the participants to the diet
regimen and we did not attempt to blind the investigators during
the study or data analysis.
Providing dietary programmes to participants
For the group based programmes (Weight Watchers and
Rosemary Conley), participants attended the most convenient
class and we reimbursed the costs of joining and attending one
class each week. Both parent companies signed a contract com-
mitting to the provision of standard care. For Slim-Fast, we reim-
bursed the cost of up to two meal replacements each day and
provided a copy of the Slim-Fast support pack. We gave partici-
pants in the Atkins group a copy of Dr Atkins’ New Diet
Revolution.8 We asked the members of the control group to
maintain their current diet and exercise pattern and offered
them any of the diets for six months at the end of study (free of
charge). All participants could claim reimbursement of travel
costs.
Study protocol and monitoring
Measures at baseline, two months, and six months included
weight, height, waist circumference, blood pressure, and fasting
blood and body fat by whole body dual x ray absorptiometry. We
excluded the absorptiometry data of four participants from all
analyses because of errors at baseline. Monthly test centre meas-
urements recorded weight in light clothing, blood pressure, and
waist circumference. We monitored renal function in the Atkins
group by urea, electrolytes, and cystatin C, and these measures
remained within the reference ranges.10 Participants completed a
seven day diet and activity diary at baseline, eight weeks, and 24
weeks. We gave no dietary or exercise advice so as not to
compromise the study.When we analysed the food diaries at two
months we found that some of the participants on the Atkins diet
were not taking supplements of micronutrients as advised in the
book. Therefore, from week 10 we offered free daily supplements
of multivitamins. All participants who withdrew completed a
short exit questionnaire. At 12 months, we recorded the weight
and dieting behaviour from six to 12 months of all participants
still willing to attend test centres.
Statistical analysis
The primary analysis was on an intention to treat basis, with
baseline values carried forward to replace missing values (one
participant was not used in this analysis as she withdrew because
of pregnancy). A secondary analysis focused on the outcomes of
these dietary approaches in the most motivated subjects who
provided complete data (baseline, two months, and six months).
Analysis of variance showed that the test centre did not affect
total weight loss in participants who completed. Attrition rates
did not differ between centres, so we analysed data from all par-
ticipants together. Baseline weight correlated with total weight
loss (r= 0.33, P < 0.001) and was therefore used as a covariate in
the analysis of weight loss over time, which uses repeated meas-
ures analysis of covariance. In the intention to treat analysis, we
used ANOVA to examine differences between groups; where
ANOVA indicated a significant group effect, we performed post
hoc pairwise testing with Tukey’s HSD (honestly significantly dif-
ferent) test. Before parametric testing, we assessed homogeneity
of variance with Levene’s statistic and tested for normal distribu-
tion; we used Welch’s F statistic if variance of the dependent vari-
able was not equal across groups. We analysed differences
between participants who completed and withdrew with t tests
for continuous variables (such as age) and 2 for categorical vari-
ables (such as sex and diet group).
Recruited (n=300)
Randomised (n=293): 214 (73%) women, 79 (27%) men
Slim-Fast
  (n=59)
Men (n=17)
Women (n=42)
(n=0)
Rosemary Conley
  (n=58)
Men (n=16)
Women (n=42)
(n=3)
Control group
  (n=61)
Men (n=15)
Women (n=46)
(n=14)
Follow-up
measures
Atkins diet
  (n=57)
Men (n=15)
Women (n=42)
(n=2)
Weight Watchers
  (n=58)
Men (n=16)
Women (n=42)
Slim-Fast
54
49
46
42
30
42
42
(men 12,
women 30)
58*
Rosemary Conley
52
46
43
40
30
41
41
(men 10,
women 31)
58
Control group
46
41
38
37
28
40
40
(men 10,
women 30)
61
Atkins diet
50
46
42
38
24
40
40
(men 13,
women 27)
57
Weight Watchers
56
52
48
49
35
47
47
(men 14,
women 33)
58
Withdrew (dissatisfied
with allocated group) (n=1)
Excluded after baseline tests (n=7):
  Not eligible for study (n=4)
  Withdrew consent (n=3)
Week
4
8
12
16
20
24
Included in analysis
of participants who
completed (n=210)
Included in
intention to treat
*1 excluded because of pregnancy
Fig 1 Flow of participants through the BBC diet trials
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Results
Table 1 shows the baseline demographics and anthropometric
measures. The mean time spent on the diet was 24.3 (SD 1.56)
weeks and did not differ between diet groups (F= 2.0, P = 0.12).
Weight and fat loss
Monthly weight loss by using all available data (fig 2) was high
initially but then slowed. Mean weight loss was significantly
higher in the Atkins group than in the other diet groups during
the first four weeks (F= 6.9, df = 3, P < 0.001): Atkins 4.4 kg (SD
2.45, range 13.5 to 0.3 kg),Weight Watchers 2.86 kg (2.23, 12.9 to
− 0.9 kg), Slim-Fast 2.68 kg (2.33, 9.4 to − 1.8 kg), and Rosemary
Conley 3.17 kg (2.02, 8.1 to − 2.0 kg). At other time points, mean
weight loss did not vary significantly between the diet groups
(table 2).
Loss of body fat showed similar patterns (table 2). In the first
two months, the greatest loss of body fat was seen in the Atkins
group; this loss was not significantly different from that seen in
the Weight Watchers or Rosemary Conley groups, but it was sig-
nificantly greater than that seen in the Slim-Fast group. Fat loss
was significantly greater in all four diet groups than in the
control group. Between two and six months, fat loss (kg and per-
centage) slowed down, and the diets groups did not differ signifi-
cantly. Between baseline and six months fat loss did not differ
between diet groups, but fat loss in all diet groups was
significantly greater than in the control group. All diets resulted
in a reduction in waist circumference. Waist reduction (at six
months) was highly correlated with total weight loss (r= 0.81,
P < 0.001) and moderately correlated with percentage of body
fat lost (r= 0.64, P < 0.001).
Table 1 Mean baseline characteristics of participants in the BBC diet trials allocated to different diet regimens. Values are mean (SD)
Characteristic Atkins diet (n=57) Weight Watchers (n=58) Slim-Fast (n=59) Rosemary Conley (n=58) Controls (n=61)
Age (years) 40.9 (9.7) 39.9 (10.9) 38.9 (10.7) 40.6 (10.3) 40.8 (9.6)
Weight (kg) 90.3 (12.7) 88.8 (13.3) 90.1 (14.1) 89.8 (12.9) 87.9 (13.5)
Body mass index (kg/m2) 31.9 (2.2) 31.2 (2.7) 32.2 (3.0) 31.6 (2.6) 31.5 (2.9)
Body fat (kg)* 35.7 (6.0) 34.2 (6.9) 35.6 (6.5) 34.5 (7.6) 33.4 (6.5)
Body fat (%) 40.9 (6.6) 39.7 (7.1) 40.6 (6.5) 39.6 (7.7) 39.4 (6.8)
Waist circumference (cm) 102 (10.6) 100 (10.3) 101 (11.5) 100 (9.8) 100 (10.1)
Blood pressure (mm Hg):
Systolic 135 (15.1) 127 (15.1) 129 (17) 130 (14.8) 130 (16.1)
Diastolic 83 (10.7) 80 (10.7) 81 (11.5) 82 (10.3) 81 (9.6)
Glucose (mmol/l)† 5.47 (0.5) 5.46 (0.5) 5.53 (0.6) 5.6 (0.6) 5.48 (0.5)
Total cholesterol (mmol/l)† 5.77 (0.9) 5.58 (1.1) 5.47 (1.1) 5.63 (0.95) 5.80 (1.1)
*Not measured in all participants: 57 for Weight Watchers, 56 for Rosemary Conley, 60 for controls.
†Not measured in all participants: 56 for Atkins diet, 57 for Rosemary Conley, 59 for controls.
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Fig 2 Weight loss during the BBC diet trials
Table 2 Intention to treat analysis of main outcome indicators in participants in the BBC diet trials allocated to different diet regimens
Outcome Atkins diet (n=57) Weight Watchers (n=58) Slim-Fast (n=58) Rosemary Conley (n=58) Controls (n=61)
Weight loss (kg)
0-2 months 5.2 (4.4) 4.7 (3.2) 3.7 (3.5) 4.0 (3.3) 0.4 (1.8)
2-6 months 1.3 (3.1) 2.2 (3.0) 1.4 (2.8) 2.4 (3.4) −0.9 (1.6)
0-6 months 6.0 (6.4) 6.6 (5.4) 4.8 (5.6) 6.3 (6.1) −0.6 (2.2)
Weight loss (%)
0-2 months 5.5 (4.2) 5.1(3.5) 3.8 (3.4) 4.5 (3.6) 0.4 (2.2)
2-6 months 1.3 (3.1) 2.4 (3.4) 1.3 (2.9) 2.7 (3.7) −1.2 (1.9)
0-6 months 6.2 (6.2) 7.3 (6.1) 4.9 (5.5) 7.0 (6.6) −0.6 (2.7)
Fat loss (kg)*
0-2 months 3.5† (3.0) 3.1 (2.4) 2.3† (2.3) 2.5 (2.1) 0.2 (1.3)
2-6 months 1.2 (2.3) 2.0 (2.3) 1.2 (2.6) 2.1 (2.5) −0.5 (1.2)
0-6 months 4.6 (4.8) 5.0 (4.3) 3.4 (4.3) 4.5 (4.3) −0.3 (4.4)
Fat loss (%)
0-2 months 1.9† (1.9) 1.6 (1.9) 1.0† (1.4) 1.5 (1.5) 0.1 (1.4)
2-6 months 1.3 (1.9) 2.0 (2.0) 1.2 (2.4) 2.1 (2.4) −0.0 (1.0)
0-6 months 3.1 (3.3) 3.6 (3.3) 2.1 (2.9) 3.4 (3.5) 0.1 (1.6)
Reduction in waist circumference (cm)
0-2 months 6.7 (6.1) 5.5 (5.1) 4.8 (4.6) 4.5 (5.3) 1.0 (4.0)
2-6 months 2.4 (4.0) 3.0 (3.5) 2.1 (3.4) 3.0 (4.2) −0.3 (2.4)
0-6 months 8.1 (7.4) 8.3 (7.0) 6.4 (6.3) 7.2 (7.2) 0.8 (3.8)
For all variables reported, the control group was significantly different from all other groups (P<0.001).
*Not measured in all participants: 57 for Weight Watchers, 56 for Rosemary Conley, 60 for controls.
†Pairwise comparison of group means with post hoc Tukey’s HSD (honestly significantly different) test found a significant difference between the Atkins and Slim-Fast groups.
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Cardiac risk factors
We found few significant differences in cardiac risk factors
between the diets groups and the control group (table 3).
Initially, the fall in systolic pressure in the Atkins group was sig-
nificantly greater than in the Slim-Fast group but not the other
groups, probably because of the relatively greater initial weight
loss in the Atkins group. Regression analysis showed that total
weight loss over time had the greatest influence on systolic and
diastolic pressure (adjusted R2 0.61 for change in systolic
pressure and 0.79 for change in diastolic pressure).
Glucose concentrations fell slightly over time; only in the
Weight Watchers group was fasting glucose significantly lower
than in the control group. In the first two months, a significant
but small drop in total cholesterol was seen in all diet groups
except for the Atkins group. By six months, cholesterol had fallen
significantly compared with the control group only in theWeight
Watchers group (by 0.55 mmol/l).
Analysis of completers
A secondary analysis of data from participants who completed
the trial shows the range of weight lost by these highly motivated
participants, who probably adhered most strongly to the
randomly allocated diets. Figure 3 shows the range of total
weight lost; some participants lost more than 25 kg over the six
month study period, whereas others gained weight (fig 3).
After six months all diets resulted in a clinically useful mean
reduction in percentage body weight: Rosemary Conley 9.9%
(SD 5.6%),Weight Watchers 9.0% (5.6%), Atkins 8.9% (5.6%), and
Slim-Fast 6.8% (5.3%); no significant differences were seen
between the diets but all were more successful than no diet (con-
trols gained 0.95%, 3.3%). The proportion of participants who
completed the trial and lost at least 10% of their body weight at
six months was 46% for the Rosemary Conley group, 45% for
the Atkins group, 36% for the Weight Watchers group, and 21%
for the Slim-Fast group. These losses were achieved despite the
random allocation of diets.
Compliance with the diets
Reported attendance at slimming clubs was similar at two
months (Rosemary Conley 79%, Weight Watchers 66%) and six
months (47%, 47%). Slim-Fast recommends 14 meal replace-
ments each week; participants reported 10 each week at two
months and eight at six months. With the Atkins diet, reported
portions of carbohydrate foods fell from 40 each day at baseline
to five at two months and seven at six months.
Withdrawal
Eighty three (28%) participants had withdrawn by six months
(table 4); 53 (64% of the total number) had withdrawn by week 8,
and at this time only seven (8%) participants who withdrew had
lost more than 5% of their body weight compared with 53 (25%)
who completed the trial. Older participants were significantly
more likely to complete than younger ones (mean age 41.6 (9.9)
v 36.8 (10.4); t= − 3.7, P < 0.001; 95% confidence interval 2.3 to
7.4). No differences in diet, centre, or sex were found between
participants who completed or withdrew. Withdrawal in the con-
trol group (21; 35%) was mostly because participants did not
wish to delay dieting.
Follow-up at 12 months
At 12 months, 158 participants (54% of the original sample)
returned data; 29 had originally been allocated to the Atkins diet,
33 to Weight Watchers, 33 to Slim-Fast, 35 to Rosemary Conley,
Table 3 Intention to treat analysis of changes in cardiac risk factors in participants in the BBC diet trials allocated to different diet regimens. Values are mean
(SD)
Outcome Atkins diet (n=57) Weight Watchers (n=58) Slim-Fast (n=58)
Rosemary Conley
(n=58) Controls (n=61) P value (ANOVA)
Fall in blood pressure
0-2 months:
Systolic 5.7* (12.7) 3.5 (9.6) 0.5* (11.4) 2.4 (11.2) 3.3 (11.0) 0.05
Diastolic 3.6 (8.4) 4.1 (6.8) 3.1 (7.8) 2.8 (7.1) 2.0 (7.0) 0.61
2-6 months:
Systolic 1.3 (9.8) 0.9 (10.3) 2.9 (12.4) 2.1 (9.2) −0.9 (8.3) 0.23
Diastolic 1.1 (6.3) 0.8 (6.7) −0.3 (8.6) 1.0 (5.5) −0.4 (5.7) 0.51
0-6 months:
Systolic 7.2 (11.6) 4.1 (11.7) 2.7 (10.7) 4.5 (9.8) 2.8 (11.8) 0.19
Diastolic 4.9 (8.1) 4.4 (8.6) 2.5 (8.6) 3.6 (6.0) 1.6 (7.4) 0.13
Fall in total glucose (mmol/l)
0-2 months 0.04 (0.4) 0.14 (0.5) 0.13 (0.5) 0.15 (0.5) 0.02 (0.4) 0.44
2-6 months 0.13 (0.5) 0.29 (0.6) 0.12 (0.5) 0.17 (0.5) 0.13 (0.4) 0.34
0-6 months 0.19 (0.5) 0.46* (0.6) 0.19 (0.6) 0.27 (0.5) 0.14* (0.5) 0.013
Fall in cholesterol (mmol/l)
0-2 months 0.08 (0.7) 0.44* (0.6) 0.26* (0.6) 0.35* (0.8) 0.08 (0.5) 0.001
2-6 months 0.19 (0.5) 0.11 (0.5) 0.07 (0.5) 0.08 (0.6) 0.24 (0.24) 0.24
0-6 months 0.29 (0.8) 0.55* (0.7) 0.35 (0.6) 0.5 (0.5) 0.5* (0.18) 0.013
*Pairwise comparison of group means using post hoc Tukey’s HSD (honestly significantly different) test showed a significant difference in systolic blood pressure at 2 months between the
Atkins and Slim-Fast groups; in the fall in glucose at 6 months between the control and Weight Watchers groups; in the fall in total cholesterol at 2 months between the Weight Watchers,
Rosemary Conley, and Slim-Fast groups; and in the fall in total cholesterol at 6 months between the Weight Watchers and control groups.
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Fig 3 Absolute weight loss of participants who completed the BBC diet trials
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and 28 to the control group. Dieting behaviour had changed
considerably: only 58 (45%) were still keeping to their originally
allocated diets (nine to Atkins, 20 to Weight Watchers, nine to
Slim-Fast, 20 to Rosemary Conley). Twenty five (19%) had
swapped dietary programmes and 47 (36%) were following their
own diet or exercise plan. More participants in the unsupported
programmes (Atkins diet and Slim-Fast) withdrew than in the
supported programmes (2 = 8.34, df = 3.0, P = 0.04). Partici-
pants in the control group who had switched to dieting (mean
weight loss 6.37, SD 4.5 kg) also preferred group based
approaches because just over half chose Weight Watchers.
Because so many participants changed diets (25% of men
and 29% of women), we also analysed weight loss in participants
who had maintained the diet to which they were initially
allocated (table 5). Statistical analysis is limited by sample size but
indicates that weight rebound after the initial six months was
higher in the unsupported programmes; however, all diets
resulted in a clinically useful weight loss of around 10% after 12
months in participants who had persisted with the diet allocated.
Discussion
Clinically beneficial weight loss is possible through commercially
available strategies, and reduced blood pressure and waist
circumference accompany weight loss. The four different
approaches were equally effective after six months. Reductions in
weight and body fat were seen with the Atkins diet within the first
eight weeks of dieting, so that the large weight changes seen with
low carbohydrate diets are not caused by loss of body water
alone. The Atkins diet had no detrimental effects on total choles-
terol concentrations or renal function, although the overall safety
of the diet was not tested.11
The range of absolute weight loss in participants who
completed the study was wide. Importantly, we did not try to
standardise energy intake across the groups, so that the effects
reflect the participants’ interpretation of and compliance with
the diet allocated. However, the mean absolute weight loss of
around 8 kg is comparable to other studies.12 13 Compliance with
each diet varied greatly. Weight can be lost only by a sustained
negative balance of energy, so the degree of adherence to a diet
will predict success or failure if activity levels remain constant.
More information is needed to enable health professionals to
decide which dietary approach may suit their patients. Currently,
we cannot predict the dietary approach best suited to each per-
son to lose weight and maintain weight loss in the longer term,
but it is clear that “one size does not fit all.”
Our study was used to make the BBC series on diet trials,
which featured a small number of people. Since motivation to
meet goal weights and patients’ expectations of weight loss are
key determinants of success,14 participants may have been influ-
enced by the media interest. Overall, around 5% of participants
were featured in the television programmes, and most
participants knew that they would not be filmed within the first
few weeks. Excluding data from the 15 filmed participants had
no effect on the overall statistical outcomes shown in this study.
The withdrawal rate was comparable to other longitudinal stud-
ies of weight loss.15–17
No dietary differences were apparent at six months, but
behaviour from six to 12 months points towards an advantage of
programmes based on group support. The need for a “quick fix”
and the relative lack of interest that people show in achieving
modest weight loss contribute to lack of adherence to most diets
in the long term. People who had kept to their allocated diet lost
about 10% of their weight, despite some weight rebound, but
some regression to the mean effect was seen. These results pro-
vide information on the “best effect” that the most highly
motivated subjects may hope to achieve over one year.
In conclusion, commercial weight loss programmes can help
people with uncomplicated obesity. Our study provides data on
how much weight patients can expect to lose by dieting, and
these data could help practitioners in managing patients’ some-
times unrealistic expectations of weight loss targets. The benefits
to health of modest weight loss and maintaining that loss over
long periods need to be emphasised.
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Table 4 Reasons for withdrawal from the diet
Group
Dissatisfied with
randomisation
Could not
tolerate diet
Dissatisfied with
weight loss
Non-compliant or
lost to follow-up Socioeconomic Pregnancy
Total (% of initial
cohort)
M F M F M F M F M F M F M F
Atkins diet 0 2 1 6 0 0 0 2 1 5 — 0 2 (13) 15 (36)
Weight Watchers 0 1 0 2 0 1 2 4 0 1 — 0 2 (13) 9 (21)
Slim-Fast 0 0 1 6 0 3 4 1 0 1 — 1 5 (29) 12 (29)
Rosemary Conley 2 1 0 1 1 2 1 3 2 4 — 0 6 (40) 11 (26)
Controls 2 12 — — — — 2 1 1 3 — 0 5 (33) 16 (35)
Total 4 16 2 15 1 6 9 11 4 14 1 20 (25) 63 (29)
M=male, F=female.
Table 5 Mean (SD) weight loss for participants in the BBC diet trials who completed 12 months on the diet to which they were randomly allocated
Weight loss Atkins diet (n=9) Weight watchers (n=20) Slim-Fast (n=9) Rosemary Conley (n=20) P value*
0-12 months:
Absolute weight loss (kg) 9.0 (4.1) 9.1 (6.2) 10.7 (6.2) 10.9 (4.1) 0.61
Weight loss (% of initial body weight) 10.3 (4.7) 10.3 (6.0) 11.4 (5.9) 13.1 (4.9) 0.38
6-12 months:
Absolute weight loss (kg) −1.5 (3.3) 0.45 (3.6) −1.65 (3.1) 1.2 (3.5) 0.11
*Comparison of active diets.
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What is already known about this topic
The prevalence of obesity and overweight with its
subsequent comorbidities is growing in the UK
Commercial diets are an increasingly popular option for
weight management
What this study adds
The comparative efficacy of four commercial diets was
similar
The health benefits associated with a modest loss of weight
(5-10% body weight) can be gained by people following a
range of dietary regimens for six months with little support
from health professionals
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that trial were based on expert opinion whereas we
collected our data.10 The previous model also
disregarded that pressure ulcers are rarely the reason
for people being admitted to hospital. Thus the
marginal cost of treating a pressure ulcer in hospital
may be small compared with the overall costs of hospi-
tal treatment. In this sense our analysis reflects actual
practice. Our assumption that participants remained
on the allocated surface over their entire hospital stay
is conservative; in reality patients are moved on to
standard mattresses or higher specification surfaces if
their risk of pressure ulcers changes. Given partici-
pants in the overlay group developed pressure ulcers
earlier than those on the mattresses, this assumption
will have over-estimated the cost of the mattresses, thus
strengthening our conclusions.
Although there was considerable uncertainty
around the point estimates of mean health benefits and
costs (table 2), this should not result in large uncertainty
for decision makers since even for large willingness to
pay values (see bmj.com) the probability of the overlays
being cost effective is only between 10% and 20%.11
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What is already known on this topic
No previous trial based economic evaluation has compared alternating
pressure mattresses with the less costly alternating pressure overlays
What this study adds
Alternating pressure mattresses were associated with lower costs and
greater benefits and are more likely to be cost saving than alternating
pressure overlays
Corrections and clarifications
An international standard for disclosure of clinical trial information
A couple of errors cropped up in this editorial by Fiona Godlee
(BMJ 2006;332:1107-8, 13 May). In discussing the setting up of
trial registries, Fiona mentioned the metaRegister of Clinical
Trials, but this should have been the ISRCTN Register
(http://isrctn.org) since this is where trials are uniquely registered
in accordance with international requirements. In addition, the
meeting convened by WHO to determine what information must
be disclosed at registration was in April 2005 (not 2004 as
written).
Short cuts: Two antiplatelet agents work better than one after stroke
In the final item of these Short Cuts by Alison Tonks (BMJ
2006;332:1264-5, 27 May), the number needed to treat for a
combination of aspirin and dipyridamole should have been 33.
The value of 104 that we gave (and which is given in the Lancet
paper cited) refers to the number needed to treat per year.
Effect of patient completed agenda forms and doctors’ education about
the agenda on the outcome of consultations: randomised controlled trial
We inadvertently used the wrong terminology in one of the
figures of this research article by J F Middleton and colleagues
(BMJ 2006;332:1238-41, 27 May). The cluster of boxes in figure 2
of the full version on bmj.com that state “data not available”
should have read “did not attend appointment.” In addition, a
column heading in table 2 of the full version (the table of the
print version) is incorrect: the heading spanning the last three
columns should read “Change in means (95% CI) (intervention
group-reference group)” [not “(reference group-intervention
group)”].
Randomised controlled trial of four commercial weight loss programmes
in the UK: initial findings from the BBC “diet trials”
During the writing, rewriting, and editing of this research paper
by Helen Truby and colleagues (BMJ 2006;332:1309-11, 3 June),
some small errors crept into table 3 of the full version on
bmj.com (table 2 of the print version). In the control group the
mean (SD) fall in cholesterol during 2-6 months should be 0.24
(0.6) (not 0.24 (0.24) as written) and during 0-6 months should be
0.18 (0.5) (not 0.5 (0.18)). The table footnote should have stated
that the fall in total cholesterol at 2 months in the Weight
Watchers, Rosemary Conley, and Slim-Fast groups was
significantly different from that in the control group. However,
the text is correct in explaining these differences, and the
conclusions drawn are not affected by the errors.
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